Dr. Daneker's leadership is expected to drive innovation, gr...
Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.
Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment